At a liver disease conference in Boston, one highlight is expected to be reports from Achillion about its new hepatitis C treatments, especially ACH-1625. The buzz is growing that the little biotech is attracting the attention of some players in Big Pharma.
Continue reading Inside Wall Street: The Growing Interest in Achillion’s Hepatitis Drugs
Inside Wall Street: The Growing Interest in Achillion’s Hepatitis Drugs originally appeared on DailyFinance on Mon, 01 Nov 2010 07:30:00.
Filed Under: Company News, Columns, Investing, Health Care, Bristol-Myers Squibb, Stock Picks, Merck